1
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2000
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
COMMISSION FILE NUMBER 0-26483
VAXGEN, INC.
(Exact name of Registrant as Specified in its Charter)
DELAWARE
(State or other jurisdiction of incorporation or organization)
94-3236309
(I.R.S. Employer Identification Number)
1000 MARINA BLVD., SUITE 200
BRISBANE, CALIFORNIA 94005
(Address of Principal Administrative Offices) (Zip Code)
(650) 624-1000
(Registrants Telephone Number, Including Area Code)
Securities Registered Pursuant to Section 12 (g) of the Securities Exchange Act
of 1934:
Common Stock ($.01 par value)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the registrant
was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes [X] No [ ]
The issuer has one class of common stock with 13,562,917 shares outstanding as
of April 28, 2000.
2
VAXGEN, INC.
FORM 10-Q
FOR THE QUARTER ENDED MARCH 31, 2000
TABLE OF CONTENTS
PART I. FINANCIAL INFORMATION PAGE
Item 1. Financial Statements:
Condensed Balance Sheets......................................... 1
Condensed Statements of Operations............................... 2
Condensed Statements of Cash Flows............................... 3
Notes to Condensed Financial Statements.......................... 4
Item 2. Management's Discussion and Analysis of Financial Condition
and Results of Operations:
Overview......................................................... 6
Results of Operations............................................ 8
Liquidity and Capital Resources.................................. 9
Year 2000 Compliance............................................. 11
Item 3. Quantitative and Qualitative Disclosure about Market Risk......... 11
PART II. OTHER INFORMATION
Item 2. Changes in Securities and Use of Proceeds......................... 12
Item 6. Exhibits and Reports on Form 8-K.................................. 13
Signature......................................................... 14
3
PART I - FINANCIAL INFORMATION
VAXGEN, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
CONDENSED BALANCE SHEETS
(UNAUDITED)
ITEM 1. FINANCIAL STATEMENTS
ASSETS
MARCH 31, DECEMBER 31,
2000 1999
------------- -------------
CURRENT ASSETS:
Cash and cash equivalents $ 22,373,000 $ 16,063,000
Investment securities 42,677,000 54,471,000
Interest receivable 597,000 514,000
Prepaid expenses and other current assets 1,216,000 1,151,000
------------- -------------
TOTAL CURRENT ASSETS 66,863,000 72,199,000
Property and equipment, net 2,961,000 2,856,000
Other assets 170,000 170,000
------------- -------------
TOTAL ASSETS $ 69,994,000 $ 75,225,000
============= =============
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Payable to Genentech $ 214,000 $ 817,000
Accounts payable 400,000 509,000
Accrued liabilities 2,231,000 2,629,000
Current portion of long-term obligations 31,000 31,000
------------- -------------
TOTAL CURRENT LIABILITIES 2,876,000 3,986,000
LONG-TERM OBLIGATIONS 81,000 89,000
COMMITMENTS AND CONTINGENCIES -- --
STOCKHOLDERS' EQUITY:
Preferred stock, $0.01 par value. 20,000,000 shares
authorized; none issued or outstanding -- --
Common stock, $0.01 par value. 20,000,000 shares
authorized; 13,561,917 and 13,511,565 shares issued
and outstanding at March 31, 2000 and
December 31, 1999, respectively 136,000 135,000
Additional paid-in capital 111,400,000 111,034,000
Deferred stock compensation (1,980,000) (2,225,000)
Accumulated other comprehensive income/(loss) -
Unrealized gain/(loss) on investment securities (234,000) (125,000)
Deficit accumulated during the development stage (42,285,000) (37,669,000)
------------- -------------
TOTAL STOCKHOLDERS' EQUITY 67,037,000 71,150,000
------------- -------------
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 69,994,000 $ 75,225,000
============= =============
See accompanying notes to condensed financial statements.
1
4
VAXGEN, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
CONDENSED STATEMENTS OF OPERATIONS
(UNAUDITED)
THREE MONTHS ENDED PERIOD FROM
MARCH 31, NOVEMBER 27, 1995
------------------------------- (INCEPTION) THROUGH
2000 1999 MARCH 31, 2000
------------ ------------ ----------------
OPERATING EXPENSES:
RESEARCH AND DEVELOPMENT:
Genentech charges $ 250,000 $ 240,000 $ 6,396,000
Other 3,803,000 2,798,000 27,323,000
------------ ------------ ------------
TOTAL RESEARCH AND DEVELOPMENT 4,053,000 3,038,000 33,719,000
GENERAL AND ADMINISTRATIVE:
Genentech charges -- -- 20,000
Other 1,593,000 1,006,000 13,595,000
------------ ------------ ------------
TOTAL GENERAL AND ADMINISTRATIVE 1,593,000 1,006,000 13,615,000
LOSS FROM OPERATIONS (5,646,000) (4,044,000) (47,334,000)
OTHER INCOME (EXPENSE), NET:
Investment income, net 1,034,000 285,000 5,100,000
Interest expense - Genentech -- -- (47,000)
Interest expense - other (4,000) (1,000) (4,000)
------------ ------------ ------------
TOTAL OTHER INCOME (EXPENSE), NET 1,030,000 284,000 5,049,000
------------ ------------ ------------
NET LOSS $ (4,616,000) $ (3,760,000) $(42,285,000)
============ ============ ============
BASIC AND DILUTED LOSS PER SHARE $ (0.34) $ (0.49)
WEIGHTED AVERAGE SHARES USED IN
COMPUTING BASIC AND DILUTED LOSS
PER SHARE 13,540,000 7,619,000
============ ============
See accompanying notes to condensed financial statements.
2
5
VAXGEN, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
STATEMENTS OF CASH FLOWS
(UNAUDITED)
PERIOD FROM
THREE MONTHS ENDED NOVEMBER 27, 1995
MARCH 31, (INCEPTION) THROUGH
--------------------------------- -------------------
2000 1999 MARCH 31, 2000
------------- ------------- --------------
CASH FLOWS FROM OPERATING ACTIVITIES:
NET LOSS $ (4,616,000) $ (3,760,000) $ (42,285,000)
ADJUSTMENTS TO RECONCILE NET LOSS TO NET CASH USED
IN OPERATING ACTIVITIES:
Depreciation and amortization 173,000 80,000 761,000
Amortization of premiums/(discounts) on investment
securities 196,000 (39,000) (619,000)
Stock compensation expense 202,000 -- 3,534,000
Changes in assets and liabilities:
Interest receivable (83,000) (36,000) (597,000)
Prepaid expenses and other current assets (65,000) 66,000 (1,216,000)
Other assets -- 53,000 (58,000)
Payable to Genentech (603,000) 240,000 214,000
Accounts payable and accrued liabilities (507,000) (603,000) 2,631,000
------------- ------------- -------------
NET CASH USED IN OPERATING ACTIVITIES (5,303,000) (3,999,000) (37,635,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of investment securities (4,566,000) (3,097,000) (121,678,000)
Sale and maturities of investment securities 16,055,000 3,095,000 79,386,000
Purchase of property and equipment (278,000) (159,000) (3,576,000)
Long-term lease deposits -- -- (120,000)
------------- ------------- -------------
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES 11,211,000 (161,000) (45,988,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments under capital lease obligations (8,000) -- (26,000)
Stock issued to Genentech -- -- 1,025,000
Stock issued to other founders -- -- 20,000
Stock issued in private placements -- 5,537,000 65,164,000
Stock issued in initial public offering -- -- 46,345,000
Issuance costs of private placements -- (264,000) (4,208,000)
Issuance costs of initial public offering -- -- (4,386,000)
Exercise of employees stock options 410,000 -- 1,062,000
Loans from Genentech -- -- 1,000,000
------------- ------------- -------------
NET CASH PROVIDED BY FINANCING ACTIVITIES 402,000 5,273,000 105,996,000
------------- ------------- -------------
INCREASE (DECREASE) IN CASH AND EQUIVALENTS 6,310,000 1,113,000 22,373,000
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD 16,063,000 6,818,000 --
------------- ------------- -------------
CASH AND CASH EQUIVALENTS AT END OF PERIOD $ 22,373,000 $ 7,931,000 $ 22,373,000
============= ============= =============
SUPPLEMENTAL SCHEDULE OF NON CASH FINANCING ACTIVITIES:
Equipment acquired through capital leases $ -- $ 86,000 $ 138,000
Issuance of stock through conversion of Genentech note payable $ -- $ -- $ 1,000,000
See accompanying notes to condensed financial statements.
3
6
VAXGEN, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
NOTES TO CONDENSED FINANCIAL STATEMENTS
MARCH 31, 2000
(UNAUDITED)
1. BASIS OF PRESENTATION
The unaudited condensed financial statements of VaxGen, Inc. (the "Company")
included herein have been prepared by the Company pursuant to the rules and
regulations of the Securities and Exchange Commission. Certain information or
footnote disclosure normally included in financial statements prepared in
accordance with generally accepted accounting principles have been condensed or
omitted pursuant to such rules and regulations. In the opinion of the management
of the Company, the accompanying unaudited condensed financial statements
contain all adjustments, consisting only of normal recurring adjustments,
necessary to present fairly the financial information included herein. While the
Company believes that the disclosures are adequate to make the information not
misleading, it is suggested that these financial statements should be read in
conjunction with the Company's audited financial statements contained in its
Annual Report on Form 10-K for the year ended December 31, 1999.
2. NON-CASH COMPENSATION
On April 1, 1999, the shareholders of the Company approved an increase in the
number of shares reserved for grant under the Company's 1996 Stock Option Plan
to 1,750,000 shares. This represents the measurement date for stock options
granted to employees earlier in 1999 and in 1998, which were granted subject to
stockholder approval of the plan amendment. As a result, the Company recorded
deferred compensation in the amount of $3,223,000, representing the excess of
fair market value of the common shares on April 1, 1999, $13.00 per share, over
the exercise price of the options on the date stockholder approval was obtained.
The Company has recorded charges to non-cash compensation expense of $202,000
for the portion of the vesting period lapsed for the three months ended March
31, 2000. The balance of deferred compensation is being amortized to expense
over the remaining vesting period of the options.
4
7
VAXGEN, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
3. LOSS PER SHARE
Excluded from the computation of basic and diluted loss per share, were stock
options and warrants outstanding for the purchase of 1,752,000 and 751,000
shares of common stock as of March 31, 2000 and March 31, 1999, respectively,
because the representative share increments would be antidilutive.
5
8
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND
FINANCIAL CONDITION
This discussion and analysis should be read in conjunction with our condensed
financial statements and related notes thereto appearing in Item 1 of this
report. In addition to historical information, this report contains
"forward-looking statements" that are within the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995, and that are subject to
certain risks and uncertainties that could cause actual results to differ
materially from those projected. The words "believe", "expect", "intend",
"anticipate", and similar expressions are used to identify forward-looking
statements, but their absence does not mean that such statement is not
forward-looking. Many factors could affect the Company's actual results,
including those factors described under "Factors Affecting Future Results" and
"Business" contained in the Company's Annual Report on Form 10-K for the year
ended December 31, 1999. These risk factors, among others, could cause results
to differ materially from those presently anticipated by the Company. Readers
are cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date of this report. The Company undertakes no
obligation to publicly release the results of any revisions to these
forward-looking statements that may be made to reflect events or circumstances
after the date of this report or to reflect the occurrence of anticipated
events.
OVERVIEW
In November 1995, VaxGen was formed to continue development of AIDSVAX(R) in
partnership with Genentech, Inc. ("Genentech"). In connection with our
formation, Genentech licensed to us the technology necessary for completing
development and commercialization of AIDSVAX(R).
Since our formation, we have focused on developing and testing AIDSVAX(R). We
have developed formulations of AIDSVAX(R), which focus on the predominant HIV
subtype in the Americas, Europe, the Caribbean, and Australia (subtype B) and
the predominant HIV subtype in Southeast Asia and East Asia (subtype E). We
have commenced two phase III clinical trials, one principally in North
America and one in Thailand to determine the efficacy of AIDSVAX(R). In October
1999, we completed the initial inoculation and enrollment of over 5,400 trial
volunteers for the North American phase III clinical trial, which is being
conducted in 61 clinical centers. The Thai phase III clinical trial is being
conducted in 17 clinical centers in Bangkok and is designed for 2,500 trial
volunteers.
To date, we have generated no operating revenues. We anticipate only modest
revenues from government or other grants or from collaborations with other
entities over the next three to five years. We have incurred losses since
inception as a result of research and development and general and administrative
expenses in support of our operations. As of March 31, 2000, we had a deficit
accumulated during the development stage of
6
9
$42,285,000. We anticipate incurring substantial losses over at least the next
three to four years as we complete our clinical trials, apply for regulatory
approvals, continue development of our technology and expand our operations.
We believe that our current resources will be sufficient to complete our current
phase III clinical trials, with first of the trials, the North American phase
III trial, scheduled to finish at the end of 2002. If AIDSVAX(R) receives
regulatory approval, we do not believe AIDSVAX(R) will be on the market before
2003. As a result, we expect that we will need to obtain additional debt or
equity financing, or funds from collaborative arrangements, to support
operations through commercialization of AIDSVAX(R). Our future capital
requirements depend on several factors, including:
- The progress of our current phase III clinical trials;
- The progress of other internal research and development projects;
- The need for leasehold improvements to facilities and the purchase of
additional capital equipment;
- The availability of government research grants; and
- The timing of revenue, if any, from AIDSVAX(R).
In the future, we may have additional non-cash compensation expense based on
employment agreements we have with three of our executive officers. Our
employment agreements with these officers provide for issuance of an aggregate
of 325,757 shares of common stock if:
- Our stock trades at an average price of $28.00 per share over a 30-day
period; or
- We are acquired in a transaction at a price greater than $28.00 per
share.
If the shares are issued, we will record non-cash compensation expense equal to
the aggregate value of shares on the date the $28.00 per share condition is met.
On April 1, 1999, the shareholders of the Company approved an increase in the
number of shares reserved for grant under the Company's 1996 Stock Option Plan
to 1,750,000 shares. This represents the measurement date for stock options
granted to employees earlier in 1999 and in 1998, which were granted subject to
stockholder approval of the plan amendment. As a result, we recorded deferred
compensation, representing the excess of fair market value of the common shares
on April 1, 1999, $13.00 per share, over the exercise price of the options on
the date stockholder approval was obtained. We will continue to incur non-cash
compensation expense as the balance of deferred compensation is being amortized
to expense over the remaining vesting period of the options.
7
10
RESULTS OF OPERATIONS
THREE MONTHS ENDED MARCH 31, 2000 COMPARED TO THE THREE MONTHS ENDED MARCH 31,
1999
RESEARCH AND DEVELOPMENT EXPENSES
Research and development expenses increased 33% from $3,038,000 for the three
months ended March 31, 1999 to $4,053,000 for the three months ended March 31,
2000. The increase in research and development expenses is related to the
on-going North American and Thai clinical trials along with development of
additional AIDSVAX(R) vaccines (See further discussion in "Liquidity and Capital
Resources"). These expenses included the cost for additional personnel, non-cash
compensation expense related to vesting of stock options, maintaining the new
research laboratory facility and increases in the fees paid to third parties
associated with conducting the clinical trials.
GENERAL AND ADMINISTRATIVE EXPENSES
General and administrative expenses increased 58% from $1,006,000 for the three
months ended March 31, 1999 to $1,593,000 for the three months ended March 31,
2000. The increase in general and administrative expenses was due primarily to
additional personnel hired to support the growing infrastructure, non-cash
compensation expense related to vesting of stock options, equipment expense
related to larger office facilities and certain administrative expenses
associated with being a public company.
OTHER INCOME, NET
Other income, net, consisting primarily of interest income, increased by 263%
from $284,000 for the three months ended March 31, 1999 to $1,030,000 for the
three months ended March 31, 2000. This was primarily attributed to higher
average balances of cash, cash equivalents and investment securities as a result
of funds received from the initial public offering completed during the third
quarter of 1999 and a private placement completed in the fourth quarter of 1999.
NET LOSS
Net loss for the three months ended March 31, 2000, was $4,616,000 compared to a
loss of $3,760,000 for the comparable period in 1999. The increase in net loss
was due to the increase in expenses as noted above.
8
11
LIQUIDITY AND CAPITAL RESOURCES
Cash, cash equivalents and investment securities were $65,050,000 at March 31,
2000. We have financed our operations since inception through capital provided
by Genentech and sales of our common stock. Genentech has no obligation to
provide future funding to the Company.
We completed our initial public offering ("IPO") in July 1999, in which we
issued and sold 3,565,000 shares of common stock for aggregate proceeds to us in
the amount of $46,345,000. Of the aggregate proceeds received in the IPO,
approximately $4,400,000 was used to pay costs and expenses related to the IPO,
resulting in net proceeds of approximately $42,000,000. In early 1999, we
received net proceeds of $5,273,000 from private placement financing activities,
all of which were completed prior to the IPO. In December 1999, we completed a
private placement of common stock with Vulcan Ventures, Inc., the investment
organization of Paul G. Allen. This private placement has enabled us to commence
development of AIDSVAX(R) vaccines designed to prevent infection by the other
known major subtypes of HIV, including those found in Africa, China, India and
South America. Currently, we have developed formulations of AIDSVAX(R), which
focus on the predominant HIV type in the Americas, Europe, the Caribbean and
Australia (subtype B) and the predominant HIV subtype in Southeast Asia and East
Asia (subtype E). The private placement consisted of approximately 2,174,000
shares of common stock, which resulted in proceeds, net of commissions and
private placement expenses, to us of approximately $24,000,000.
Since our inception, investing activities, other than purchases and sales of
investment securities, have consisted entirely of equipment acquisitions and
leasehold improvements. From inception through March 31, 2000, our investment in
equipment and leasehold improvements was $3,576,000. The increase in equipment
and leasehold improvements has been primarily due to the to development of our
research and development laboratory and the establishment of larger office
facilities. Net cash used for operating activities for the three months ended
March 31, 2000 was $5,303,000 representing expenditures for research and
development costs and general and administrative expenses.
In October 1999, we entered into a collaboration with the federal Centers for
Disease Control and Prevention ("CDC") to support research at six of the 56
clinics in the United States currently conducting phase III clinical trials of
our AIDSVAX(R) vaccine. The CDC selected the six sites in the fourth quarter of
1999. Contractual arrangements between the CDC and the clinics have been
completed with five of the sites, with the remaining one still pending. The
participating sites will continue to implement our phase III protocol, as well
as conduct epidemiological, social and behavioral research, which will be shared
by VaxGen and the CDC. The sites will be compensated directly by the CDC for the
clinical costs, which would have been incurred by VaxGen, and for conducting the
9
12
additional research. The CDC has agreed to contribute approximately $8,000,000
over a four year period to the participating sites.
The National Institute of Allergy and Infectious Diseases ("NIAID") is forming a
collaboration with us to obtain and store clinical specimens from our North
American phase III clinical trial. The proposal provides that NIAID would fund
approximately $4,600,000 for this program. Consummation of the collaboration
remains subject to a number of conditions, including ownership of any
intellectual property arising out of the collaboration. If these matters are not
resolved on terms acceptable to us, the collaboration may not be consummated.
We believe that our existing cash and cash equivalents, investment securities
and investment income, will enable us to meet our forecasted expenditures
through the anticipated completion of our current phase III clinical trials,
which is scheduled to occur at the end of 2002. We will need to raise additional
capital to finance commercialization of AIDSVAX(R), or to continue operations if
the phase III clinical trials are not successful, are delayed or more costly
than currently anticipated, or if commercialization is delayed for any other
reason. We cannot assure you that we will be able to raise sufficient funds when
needed, or that such funds will be available on favorable terms.
Our exposure to market rate changes is related primarily to our debt securities
included in our investment portfolio. We do not have any material derivative
financial instruments. By policy, we invest in debt instruments of the U. S.
Government and high-quality corporate issuers, limit the amount of credit
exposure to any one issuer, limit duration by restricting the term, and hold
investments to maturity except under rare circumstances. Investments in both
fixed rate and floating rate interest earning instruments carry a degree of
interest rate risk. Fixed rate securities may have their fair market value
adversely impacted due to a rise in interest rates, while floating rate
securities may produce less income than expected if interest rates fall. Due in
part to these factors, our future investment income may fall short of
expectations due to changes in interest rates or we may suffer losses in
principal if forced to sell securities, which have declined in market value due
to changes in interest rates. At March 31, 2000, we held government debt
instruments in the principal amount of $15,766,000. If market interest rates
were to increase immediately and uniformly by 10% from levels at March 31, 2000,
the fair value of our portfolio would decline by an immaterial amount. Our
exposure to losses as a result of interest rate changes is managed through
investing primarily in securities that mature in a period of one year or less.
We have exposure to foreign exchange rate risk primarily related to our
conducting clinical trials in Thailand. Thailand is currently considered an
emerging economy. A material increase in the value of Thailand's currency
against the U.S. Dollar could cause an increase in our expenses. The majority of
our contracts associated with conducting clinical trials in Thailand are priced
in Baht. At the time these contracts were written, the Thailand exchange rate
was 37.5 Baht per one U. S. Dollar. As of March 31, 2000, we have incurred
$1,000 in foreign exchange losses. We are currently hedging our foreign currency
exposure in Thai Baht by purchasing forward foreign exchange contracts. We
10
13
anticipate that we will not record any material foreign exchange gains or losses
due to transactions in Thai Baht in the second quarter of 2000.
YEAR 2000 COMPLIANCE
To date, we have not experienced any disruptions in our operations relating to
Year 2000 issues. However, it is not possible to conclude that all aspects of
the Year 2000 issue that may affect us, including those relating to third
parties with whom we have material business relationships, have been resolved.
As of the date of this report, the costs to address our Year 2000 issues have
not exceeded $5,000 and all costs have been expensed as incurred.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Information relating to quantitative and qualitative disclosure about market
risk is set forth under the caption "Liquidity and Capital Resources" in Part I,
Item 2, Management's Discussion and Analysis of Financial Condition and Results
of Operations.
11
14
PART II - OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
We are not currently subject to any material legal proceedings or claims.
ITEM 2. CHANGES IN SECURITIES AND USE OF PROCEEDS
The Company's Registration Statement under the Securities Act of 1933 (File No.
333-78065) became effective June 29, 1999. Offering proceeds, net of aggregate
expenses of approximately $4,300,000, were approximately $42,000,000. All of the
expenses related to the offering were direct or indirect payments to others and
not payments to our directors or officers (or their associates) or to our
affiliates or 10% shareholders. The Company has invested the entire net proceeds
from the offering in short-term investments such as commercial paper and
government obligations. The Company has not used any of the net offering
proceeds for construction of plant, building or facilities, purchases of real
estate, acquisition of other businesses or repayment of indebtedness.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4. SUBMISSION OF MATTER TO A VOTE OF SECURITY HOLDERS
None.
ITEM 5. OTHER INFORMATION
None.
12
15
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibits required by Item 601 and Regulation S-K:
27.1 Financial Data Schedule, which is submitted
electronically to the Securities and Exchange
Commission for information purposes only and is not
deemed filed.
(b) Reports on Form 8-K:
None.
13
16
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
VaxGen, Inc.
(Registrant)
Dated: May 10, 2000 By: /s/ Carter A. Lee
---------------------------------
Carter A. Lee
Senior Vice President
Finance & Administration
(Principal Finance Officer)
14
17
EXHIBIT INDEX
Exhibit 27.1 Financial Data Schedule